Related Experiment Video
Updated: Feb 23, 2026

Development of a Nose-only Inhalation Toxicity Test Chamber That Provides Four Exposure Concentrations of Nano-sized Particles
Published on: March 18, 2019
Development of an inhalation unit risk factor for ethylene dibromide
Heather R Schaefer1, Jessica L Myers1
1a Texas Commission on Environmental Quality, Toxicology Division , Austin , TX , USA.
Texas developed a new inhalation unit risk factor for ethylene dibromide (EDB) to protect public health. This factor, based on rat cancer studies, helps limit exposure to this chemical in ambient air.
Area of Science:
- Environmental Toxicology
- Chemical Risk Assessment
- Public Health Science
Background:
- The Texas Commission on Environmental Quality (TCEQ) establishes toxicity factors for airborne chemicals.
- Ethylene dibromide (EDB) is a chemical emitted in Texas requiring updated toxicity assessments.
Purpose of the Study:
- To develop an inhalation unit risk factor (URF) for ethylene dibromide (EDB).
- To establish a health-protective air concentration for chronic EDB exposure.
Main Methods:
- Utilized data from a National Toxicology Program (NTP) 2-year inhalation cancer bioassay on EDB.
- Applied benchmark concentration (BMC) modeling and animal-to-human dosimetric adjustments.
- Identified nasal cavity adenocarcinomas in female rats as the critical carcinogenic endpoint.
Main Results:
- The URF for EDB was calculated as 3.4E-04 per ppb (4.4E-05 per µg/m³).
- The 95% lower confidence limit of the BMC at the 10% excess risk level (BMCL10) was 292.8 ppb.
- A lifetime air concentration of 0.029 ppb (0.22 µg/m³) corresponds to a one in 100,000 excess cancer risk.
Conclusions:
- The developed URF is based on the most sensitive tumorigenic effect in the most sensitive species and sex.
- The established air concentration is considered sufficiently health-protective for the general public.
- This URF will aid in managing potential carcinogenic risks from chronic EDB exposure in ambient air.
Related Concept Videos
Inhalational Anesthetics: Overview
Autoxidation of Ethers to Peroxides and Hydroperoxides
Inhaled Medications
Pulmonary Cycle: Exhalation
Asthma-I: Introduction
Chronic Obstructive Pulmonary Disease-I: Introduction

